Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency

Abstract Background Acute myeloid leukemia with myelodysplasia‐related changes (AML‐MRC) generally confers poor prognosis, however, patient outcomes are heterogeneous. The impact of TP53 allelic state and variant allele frequency (VAF) in AML‐MRC remains poorly defined. Methods We retrospectively ev...

Full description

Bibliographic Details
Main Authors: Davidson Zhao, Entsar Eladl, Mojgan Zarif, José‐Mario Capo‐Chichi, Andre Schuh, Eshetu Atenafu, Mark Minden, Hong Chang
Format: Article
Language:English
Published: Wiley 2023-03-01
Series:Cancer Medicine
Subjects:
AML risk stratification
AML‐MRC
next‐generation sequencing
TP53 mutation
Online Access:https://doi.org/10.1002/cam4.5421

Internet

https://doi.org/10.1002/cam4.5421

Similar Items